Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNa combined with chemotherapy

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3791-3800

  Sterman, Daniel H ^a,f,h   Alley, Evan ^b   Stevenson, James P ^b   Friedberg, Joseph ^c   Metzger, Susan ^a   Recio, Adri ^a   Moon, Edmund K ^a   Haas, Andrew R ^a   Vachani, Anil ^a   Katz, Sharyn I ^b   Sun, Jing ^a   Heitjan, Daniel F ^a   Hwang, Wei Ting ^a   Litzky, Leslie ^a   Yearley, Jennifer H ^d   Tan, Kay See ^a,g   Papasavvas, Emmanouil ^e   Kennedy, Paul ^a   Montaner, Luis J ^e   Cengel, Keith A ^b   Ii, Charles B Simone ^b   Culligan, Melissa ^c   Langer, Corey J ^b   Albelda, Steven M ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e WISTAR INSTITUTE   (United States)

^f SOUTHERN METHODIST UNIVERSITY   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; CANCER ANTIBODY; CARBOPLATIN; CELECOXIB; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; AGED; ALOPECIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CUSHINGOID SYNDROME; CYTOKINE RELEASE SYNDROME; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGITIS; FATIGUE; FEASIBILITY STUDY; FEMALE; HAND PARESTHESIA; HEADACHE; HICCUP; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOALBUMINEMIA; HYPOXIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURAL PAIN; PLEURISY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; RHINITIS; RHINORRHEA; RIGOR; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TINNITUS; TREATMENT RESPONSE; VERTIGO; VOMITING; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; CANCER STAGING; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOTHERAPY; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84980426841     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2133     Document Type: Article

References (33)

1. Ai J, Stevenson JP. Current issues in malignant pleural mesothelioma evaluation and management. Oncologist 2014;19:975-84.
2. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collová E, et al. Second-line chemotherapy in malignant pleural mesothemioma: Results of a retrospective multicenter survey. Lung Cancer 2012;75:360-67.
3. Vachani A, Moon E, Wakeam E, Albelda SM. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010;42:385-93.
4. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al. A phase I clinical trial of single-dose Intrapleural INF-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007;13:4456-66.
5. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, et al. A phase I trial of repeated Intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusion. Mol Ther 2010;18:852-60.
6. Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, et al. A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011;184: 1395-9.
7. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89:884-93.
8. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, et al. Pleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460-7.
9. Arico E, Belardelli F. Interferon-alpha as antiviral and antitumor vaccine adjuvants: Mechanisms of action and response signature. J Interferon Cytokine Res 2012;32:235-47.
10. Majhen D, Calderon H, Chandra N, Fajardo CA, Rajan A, Alemany R, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 2014;25:301-17.
11. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol 2013;190:850-6.
12. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, et al. Cyclooxygenase-2 inhibition augments efficacy of a cancer vaccine. Clin Cancer Res 2006;12:214-22.
13. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, et al. Chemotherapy delivered after viral immune-gene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010;18:1947-59.
14. Lake RA, Robinson BWS. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005;5:397-405.
15. McCoy MJ, Nowak AK, Lake RA. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens 2009;74:1-10.
16. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
17. de Biasi AR, Vliiena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 2014;20:5384-91.
18. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-60.
19. Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, et al. Immunological effects of anti-transforming growth factor-beta (TGF-beta) antibody GC1008 in cancer patients with malignant pleural mesothelioma (MPM). Oncoimmunology 2013;8:e26218.
20. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95.
21. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 2006;55:1122-31.
22. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8 T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28:710-22.
23. Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, et al. Increased frequency of ICOS CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013:1:229-34.
24. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019-31.
25. Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013;31:2369-71.
26. Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 2013;35:123-37.
27. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014;11:509-24.
28. Palena C, Schlom J. Vaccines against human carcinoma: strategies to improve antitumor immune responses. J Biomed Biotechnol 2010;2010: 380697.
29. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010;15:969-75.
30. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94.
31. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14:1104-11.
32. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97.
33. Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014;111:1860-69.